MD Anderson Receives $1.82 Million NCI Grant to Investigate Bhlhe40 Transcription Factor as Novel Target for Improving Immunotherapy Response
核心洞察
MD Anderson Cancer Center has been awarded a $1.82 million NCI R01 renewal to study the transcription factor Bhlhe40 (搜索) in T cell function during immune checkpoint therapy.
Preclinical data show that anti-PD-1 and anti-CTLA-4 treatment strongly upregulates Bhlhe40 (搜索) in tumor antigen-specific CD4 and CD8 T cells, and its deletion renders mice unable to reject ICT-sensitive tumors.
The research will employ single-cell RNA sequencing, scATAC-seq, ChIP-seq, and CODEX multiplex imaging to dissect Bhlhe40 (搜索)'s role in chromatin accessibility and transcriptional programs across T cell compartments.
The University of Texas MD Anderson Cancer Center has received a $1.82 million National Cancer Institute R01 renewal grant to investigate how the transcription factor Bhlhe40 (搜索) governs T cell effector function during immune checkpoint therapy (ICT) and neoantigen cancer vaccines. The research, led by principal investigator Matthew M. Gubin, could identify a novel therapeutic target for improving response rates in patients who fail current immunotherapies.
The grant renewal builds on compelling preclinical findings from Gubin's laboratory that position Bhlhe40 (搜索) as a critical regulator of anti-tumor immunity.
Preclinical Evidence Establishes Bhlhe40 (搜索) as Essential for ICT Response
Preclinical data demonstrated that treatment with anti-PD-1 and anti-CTLA-4 strongly upregulates Bhlhe40 (搜索) in tumor antigen-specific CD4 and CD8 T cells in both sarcoma (搜索) and melanoma (搜索) mouse models. When researchers conditionally deleted Bhlhe40, mice became unable to reject ICT-sensitive tumors — a striking functional outcome that underscores the transcription factor's essential role in mediating immunotherapy efficacy.
Further mechanistic analysis revealed that Bhlhe40 (搜索)-deficient T cells exhibited reduced interferon-gamma production and impaired remodeling of intratumoral macrophages, suggesting that Bhlhe40 orchestrates multiple facets of the anti-tumor immune response beyond T cell-intrinsic effector function.
Research Program to Dissect CD4 and CD8 Compartment-Specific Mechanisms
The renewed grant will deploy an advanced suite of technologies to resolve questions left unanswered by the earlier work. The research program will utilize T cell-specific knockout models, single-cell RNA sequencing, scATAC-seq, ChIP-seq, and CODEX multiplex imaging to dissect how Bhlhe40 (搜索) controls chromatin accessibility and transcriptional programs in both CD4 and CD8 compartments — a distinction the initial studies did not fully resolve.
A third aim of the grant will translate preclinical findings to human biology by manipulating Bhlhe40 (搜索) expression in human T cells and analyzing pre- and post-treatment patient material, establishing a direct line from mechanistic discovery to clinical relevance.
CD4 T Cells Gain Prominence in Immuno-Oncology
The deliberate focus on CD4 T cells alongside CD8 cells reflects a broader shift in the immuno-oncology field, where helper T cell contributions to durable tumor rejection are increasingly recognized as essential rather than ancillary. This evolving understanding has prompted researchers to look beyond the CD8-centric paradigm that has dominated immunotherapy development.
A Mechanistically Grounded but Early-Stage Target
Bhlhe40 (搜索) currently has no clinical-stage inhibitors or activators, positioning it as an early-stage but mechanistically grounded target. Competing approaches to addressing T cell dysfunction — including next-generation checkpoint combinations, tumor-infiltrating lymphocyte (TIL) therapies, and transcription factor-focused programs targeting TOX or NR4A — underscore both the therapeutic opportunity and the increasingly crowded landscape for improving ICT response rates.